Business
Spectral to Present at Microcap Rodeo's Spring into Action Best Ideas Virtual Conference on May 16th
TORONTO, ON / ACCESSWIRE / May 13, 2022 / Spectral Medical Inc. ("Spectral" or the "Company")...
About this update from Spectral Medical Inc
[{"type":"text","content":"Spectral to Present at Microcap Rodeo’s Spring into Action Best Ideas Virtual Conference on May 16thTORONTO, ON / ACCESSWIRE / May 13, 2022 / Spectral Medical Inc. (\"Spectral\" or the \"Company\") (TSX:EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly-owned subsidiary Dialco Medical Inc. (\"Dialco\"), today announced that Chris Seto, CEO and Dr. Jon Kellum, CMO of Spectral Medical, have been invited to present at the Spring Into Action - Best Ideas Investor Conference, which is being held virtually May 16th-20th, 2022.Management is scheduled to present on Monday, May 16, 2022 at 3:00 p.m. ET. The presentation will be webcast live and available for replay at https://www.webcaster4.com/Webcast/Page/2882/45565. Management will also be available for one-on-one meetings with qualified investors throughout the conference.To receive additional information, request an invitation or to schedule a one-on-one meeting, please email [email protected] can register for the conference here.About the MicroCap Rodeo Spring Into Action Best Ideas ConferenceThe MicroCap Rodeo is back with its \"Best Ideas Bowl.\" This conference is a virtual conference that brings you the top 36 best ideas. Qualified institutional investors recommended each of the 36 companies represented as one of their best ideas. Those of you who attended the 2019 MicroCap Rodeo in Austin, Texas, know that we're focused on alpha.About SpectralSpectral is a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ (\"PMX\"). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis.PMX is approved for therapeutic use in Japan and Europe, and has been used safely and effectively on more than 340,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. Approximately 330,...